Special Issue "The COVID Vaccine"
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (11 October 2022) | Viewed by 179443
Special Issue Editors
Interests: functional biomaterials; tissue engineering; cell therapy; nano drug delivery system; stem cells; cellular microenvironment
Special Issues, Collections and Topics in MDPI journals
Interests: cell engineering; surface modification; biomimetic materials; tissue engineering; hydrogels
Special Issues, Collections and Topics in MDPI journals
Interests: nano-bioengineering; biopharmaceutics; nanovaccine; lipid and polymer nanocarrier
Interests: nano-bioengineering; biopharmaceutics; nanovaccine; lipid and polymer nanocarrier
Special Issue Information
Dear Colleagues,
The ongoing pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has wreaked havoc worldwide, infecting over 106,520,390 people and killing at least 2,324,050 as of the mid–end of Feb 2021. Currently, less than 0.3% of the global population has received a full dose of a COVID-19 vaccination, emphasizing the urgent need for mass COVID-19 vaccine development, manufacturing, and distribution. Development was initiated when the genetic sequence of the virus became available in early January 2020 and after a sizable array of vaccine candidates are being engaged for the development of safe and effective Covid-19 vaccine including the DNA, mRNA, subunit proteins, and virus-based vaccines such as inactivated, live-attenuated, and recombinant viral vaccines. There are currently more than 180 vaccine candidates at various stages of development. Among these, currently, 67 vaccines are being tested in clinical trials on humans, and 20 have reached the final phases of clinical trials. More than 90 vaccines are under active preclinical investigation in animals. However, the mechanism actions of approved and investigative COVID-19 vaccine are not clear, as several factors influence the immunogenicity of COVID-19 vaccines including antigen, adjuvant, excipients, and route of administration are among the few. Additionally, the two approved mRNA-lipid nanoplatforms based on COVID-19 vaccines have created a new success pathway for nanoplatform-mediated delivery of genetic materials that potentially revolutionize the nanomedicine field. Therefore, we invite you to submit a research article or a review article discussing the different COVID- 19 antigen, adjuvant, and novel development and investigation on its mechanisms of action, advanced manufacturing, and characterization methods and preclinical investigations.
The specific themes are as follows:
- Novel COVID-19- vaccine delivery platforms including nano/microcarriers or delivery systems.
- Application of biomaterials in COVID -19 vaccine developments
- Investigations on the different route of administration such as nasal, transdermal, and intravenous methods
- Insight on the molecular and immunological mechanisms of different COVID-19 antigen and adjuvants candidates, nano and microcarriers modes of action, immunogenicity, and adverse effects
- Vaccine manufacturing scale-up and characterization.
Prof. Dr. Soo-Hong Lee
Prof. Hansoo Park
Dr. Jagathesh Chandra Rajendran
Dr. K.S Jaganathan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- vaccines